摘要
几项研究表明, 在阿尔茨海默病(AD)中,可溶性淀粉样β(Aβ)oligomer-induced异常的神经元细胞周期重新初始对于引发神经退化和损失是一个重要组成部分。在这项研究中,我们调查了Ras的角色,这是一个众所周知的protooncoprotein,在可溶性Aβoligomer-induced异常的神经元细胞周期激活和随后的细胞损失重可以用维甲酸分化人类SH-SY5Y神经母细胞瘤细胞作为模型系统。依据之前的文献,我们表明,体外制剂的可溶性Aβ42寡聚物引发细胞周期激活不止是细胞增殖。作为一个新的发现,我们表明,Farnesylthiosalicylic酸(FTS),一个特定的化学Ras抑制剂,防止可溶性Aβ42低聚物preparation-induced细胞周期激活。此外,我们表明,占主导地位的消极的表达突变体h(S17N)防止可溶性Aβ42低聚物preparation-induced细胞周期的激活,确认特定角色的Ras途径。作为一种可能的情况更好地模仿阿尔茨海默病人的大脑,我们准备从Aβ42可溶性低聚物:Aβ40(3:7)肽混合物着手,表明这种低聚物制备同样诱导细胞周期激活也是Ras抑制剂所抑制的。最后,我们表明, 在我们的视黄酸分化SH-SY5Y细胞中FTS防止可溶性Aβ42低聚物preparationinduced细胞死亡。总体而言,我们的研究结果有力地表明,Ras活动需要可溶性Aβoligomer-induced异常的神经元细胞,和随后的神经损失,这被认为是AD发病的重要机制。
关键词: 阿尔茨海默氏症、淀粉样βAβ42 / Aβ40比率、细胞周期、farnesylthiosalisylic酸、低聚物。
Current Alzheimer Research
Title:Targeting Ras Activity Prevented Amyloid Beta-Induced Aberrant Neuronal Cell Cycle Re-Entry and Death
Volume: 13 Issue: 11
Author(s): M. Murat Koseoglu, Bagdeser Akdogan Ozdilek, Umidahan Djakbarova, Ayse Gulusur
Affiliation:
关键词: 阿尔茨海默氏症、淀粉样βAβ42 / Aβ40比率、细胞周期、farnesylthiosalisylic酸、低聚物。
摘要: Several studies suggest that soluble Amyloid β (Aβ) oligomer-induced aberrant neuronal cell cycle re-entry is the initial trigger for a significant part of the neuronal degeneration and loss in Alzheimer's disease (AD). In this study, we investigated the role of Ras, which is a well-known protooncoprotein, in soluble Aβ oligomer-induced aberrant neuronal cell cycle activation and subsequent cell loss using retinoic acid differentiated human SH-SY5Y neuroblastoma cells as model system. In line with previous literature, we showed that in vitro preparations of soluble Aβ42 oligomers triggered cell cycle activation but not cell proliferation. As a new finding, we showed that Farnesylthiosalicylic acid (FTS), a specific chemical Ras inhibitor, prevented soluble Aβ42 oligomer preparation-induced cell cycle activation. Moreover, we showed that the expression of dominant negative mutant H-Ras (S17N) prevented soluble Aβ42 oligomer preparation-induced cell cycle activation, confirming the specific role of Ras in this pathway. As a possible better mimic of the situation in the AD brain, we prepared soluble oligomers from Aβ42 : Aβ40 (3:7) peptide mixture and showed that this oligomer preparation similarly induced cell cycle activation which was also inhibited by the Ras inhibitor. Finally, we showed that FTS prevented soluble Aβ42 oligomer preparationinduced cell death in our retinoic acid differentiated SH-SY5Y cells. Overall, our results strongly suggest that Ras activity is required for soluble Aβ oligomer-induced aberrant neuronal cell cycle reentry and subsequent neuronal loss, which are considered important mechanisms in AD pathogenesis.
Export Options
About this article
Cite this article as:
M. Murat Koseoglu, Bagdeser Akdogan Ozdilek, Umidahan Djakbarova, Ayse Gulusur , Targeting Ras Activity Prevented Amyloid Beta-Induced Aberrant Neuronal Cell Cycle Re-Entry and Death, Current Alzheimer Research 2016; 13 (11) . https://dx.doi.org/10.2174/1567205013666160625074520
DOI https://dx.doi.org/10.2174/1567205013666160625074520 |
Print ISSN 1567-2050 |
Publisher Name Bentham Science Publisher |
Online ISSN 1875-5828 |
- Author Guidelines
- Graphical Abstracts
- Fabricating and Stating False Information
- Research Misconduct
- Post Publication Discussions and Corrections
- Publishing Ethics and Rectitude
- Increase Visibility of Your Article
- Archiving Policies
- Peer Review Workflow
- Order Your Article Before Print
- Promote Your Article
- Manuscript Transfer Facility
- Editorial Policies
- Allegations from Whistleblowers
- Announcements
Related Articles
-
Targeted Lipid Nanoparticles for Antisense Oligonucleotide Delivery
Current Pharmaceutical Biotechnology Targeted Therapies in Lung Cancers: Current Landscape and Future Prospects
Recent Patents on Anti-Cancer Drug Discovery The NK-1 Receptor is Involved in the Antitumoural Action of L-733,060 and in the Mitogenic Action of Substance P on Human Pancreatic Cancer Cell Lines
Letters in Drug Design & Discovery The High Mobility Group A1 (HMGA1) Transcriptome in Cancer and Development
Current Molecular Medicine Recent Development of Peptide Drugs and Advance on Theory and Methodology of Peptide Inhibitor Design
Medicinal Chemistry Metabolic Aspects of Prion Diseases: An Overview
Current Drug Targets Metabolism and the Paradoxical Effects of Arsenic: Carcinogenesis and Anticancer
Current Medicinal Chemistry Imaging of EGFR and EGFR Tyrosine Kinase Overexpression in Tumors by Nuclear Medicine Modalities
Current Pharmaceutical Design Approaches to Target Profiling of Natural Products
Current Medicinal Chemistry Anti-Cancer Cytotoxic Effects of Multiwalled Carbon Nanotubes
Current Pharmaceutical Design Editorial
Anti-Inflammatory & Anti-Allergy Agents in Medicinal Chemistry Current Therapy of Drugs in Amyotrophic Lateral Sclerosis
Current Neuropharmacology Role of mTOR in Hematological Malignancies
Current Cancer Therapy Reviews Vascular Endothelial Growth Factor and Vascular Endothelial Growth Factor Receptor Inhibitors as Anti-Angiogenic Agents in Cancer Therapy
Recent Patents on Anti-Cancer Drug Discovery Small Interfering RNAs and Antisense Oligonucleotides for Treatment of Neurological Diseases
Current Drug Targets Functionalized Silver Nanoparticles for Sensing, Molecular Imaging and Therapeutic Applications
Current Nanomedicine Tumor Vasculature Targeting Through NGR Peptide-Based Drug Delivery Systems
Current Pharmaceutical Biotechnology Role of Cannabinoids and Endocannabinoids in Cerebral Ischemia
Current Pharmaceutical Design Cell Metabolism Under Microenvironmental Low Oxygen Tension Levels in Stemness, Proliferation and Pluripotency
Current Molecular Medicine Irreversible LSD1 Inhibitors: Application of Tranylcypromine and Its Derivatives in Cancer Treatment
Current Topics in Medicinal Chemistry